Chiesi is offering $27-per-share for Framingham, Massachusetts-based KalVista, valuing the company at around $1.9 billion, ...

Board‑level appointments this month were thick and fast, with six Boards adding new faces as Chairperson, as well as several ...

Delivering a shared agenda for the UK’, it explored how to ensure NHS patients benefit from the latest medicines and vaccines ...

The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur, saying this could ...

GSK has had a solid start to 2026, with revenues rising ahead of analyst expectations in the first full quarter under new ...

A study has found evidence that 11 cancers are becoming more common among young people in England, and points to a main ...

Takeda has said it intends to move quickly ahead with regulatory filings for oveporexton, its orexin agonist for sleep disorder narcolepsy, after a clean sweep of positive efficacy data in two phase 3 ...

Biofourmis has raised $300 million in fourth-round financing, sending its value rocketing to around $1.3 billion and injecting some fresh momentum into the digital health sector after a slowdown in ...

After years of wrangling, OxyContin manufacturer Purdue Pharma is on the brink of a bankruptcy agreement that could allow it ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a ...

In a shock move, AstraZeneca has ditched a plan to invest £450 million ($558 million) in a new vaccine manufacturing plant in the UK, after the government reduced the offer on the table to support the ...

Sanofi's Sarclisa has played second fiddle to Johnson & Johnson's Darzalex in the treatment of multiple myeloma (MM), but the company hopes a new delivery option could give it more of a leading role.